Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

MENDHAM, N.J. and WARMINSTER, Pa., December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis...

Clover Biopharmaceuticals 三叶草新冠候选疫苗的全球2/3期临床试验结果显示对德尔塔 (Delta) 变异株的保护效力为79%

三叶草新冠候选疫苗的全球2/3期临床试验结果显示对德尔塔 (Delta) 变异株的保护效力为79% 在全球四大洲的 “ SPECTRA” 2/3期临床试验共入组了超过30,000 名成年和老年受试者,在保护效力分析中100% 的SARS-CoV-2(新冠病毒)均为变异株(Delta变异株为主)临床试验成功达到疫苗保护效力的主要终点及次要终点“...